All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

In what patients would you replace 7+3 with venetoclax-based therapies?

During the Acute Leukemia Forum 2021, the AML Hub spoke to James Foran, Mayo Clinic, Jacksonville, US. We asked, In what patients would you replace 7+3 with venetoclax-based therapies?

In what patients would you replace 7+3 with venetoclax-based therapies?

Historically, older patients with AML have been undertreated due to the barriers involved in treatment with intensive chemotherapy. In this video, Foran discusses the usage of venetoclax-based therapies with a focus on this patient subset. He believes that longer follow-up and prospective data are needed in order to offer the azacitidine/venetoclax combination to more patients.

 

Share: